Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have an advanced solid tumor that has spread or cannot be removed by surgery
- Your tumor has a documented PI3K-alpha (PI3Kα) mutation that matches the trial’s required type
- You can provide a new/recent tumor sample (biopsy) or tissue sample for testing if possible
- Your body function is strong enough for treatment (ECOG score 0 or 1) and your blood/organ tests meet protocol limits
- You do not have certain recent prior cancer treatments, brain/spine symptoms from metastases, or uncontrolled diabetes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.